Download now
← Case studies
2022-03-03GovernanceRegulationsPeople

GxP QMS Framework Prepares Emerging Biopharma for Commercialization

Case study on GxP QMS Framework Prepares Emerging Biopharma for Commercialization.

Startup and emerging life sciences companies often do not have a mature and complete quality management system in place for their commercialization activities.

A strategic QMS framework will reinforce a company's quality goals by implementing a governance structure and operational and procedural practices in support of product commercialization. This case study shares how USDM helped a pre-commercial company to enhance and harmonize, its QMS to prepare for an upcoming pre-approval inspection (PAI) and meet its regulatory compliance objectives.

The Situation
  • An emerging biotechnology and pharmaceutical company with ~200 employees
  • In their pre-commercial, phase-3, late-stage clinical drug trials
  • The customer needed assistance identifying gaps and developing an implementation roadmap for their Quality Management System (QMS)
  • The roadmap defined a deployment schedule and the new GxP capabilities needing to be implemented within their QMS to prepare for commercialization
  • A strict deadline for a pre-approval inspection (PAI) was scheduled with the regulatory authority, and the customer needed a high-performance team and professional project management to accelerate the timeline
  • The project required the coordination of a large multi-functional team requiring alignment from all stakeholders to support the implementation of the new QMS
  • The customer required a cGMP training program to get the organization up to speed on the latest regulatory requirements
The Solution
  • USDM was selected for the project because of the expertise of our consultants and our extensive life sciences domain experience
  • USDM performed a gap assessment of the customer's existing QMS
  • USDM created and implemented a strategic roadmap to remediate the QMS gaps identified
  • USDM's senior program manager created a detailed timeline to ensure that the remediation of the customer's QMS was delivered ahead of schedule and without delays
  • USDM conducted the remediation and facilitated the communication and collaboration between all stakeholders to gain alignment and complete the required deliverables
  • USDM drafted 50+ SOPs and integrated the new policies and procedures within the customer's existing QMS
  • USDM developed and delivered a cGMP training curriculum program enabling the customer to educate and achieve their quality requirements

The Results

  • Less than 6 months to remediate the customer’s QMS​
  • 50+ new SOPs delivered​
  • PAI deadline achieved to meet regulatory requirements

Learn more about USDM's commercialization QMS framework.

Start here

Put AI to work in life sciences — with the right guardrails underneath.

Start with a structured AI Readiness Assessment: fixed-fee, executive-ready, and built to surface the highest-value workflows first.

  • Workflow inventory and risk classification
  • Business value and readiness scoring
  • FDA CSA + EU AI Act + ISO 42001 gap analysis
  • Prioritized 90-day roadmap by impact, risk, and effort

Start here

Talk to USDM

Tell us what workflow or outcome you want to improve and we'll map the right AI, governance, and delivery path.

By submitting this form, you agree to USDM’s Privacy Policy and consent to receive communications from USDM. You can unsubscribe at any time using the link in our emails.